4//SEC Filing
Lippis Daniel J. 4
Accession 0001225208-25-004947
CIK 0001099800other
Filed
May 8, 8:00 PM ET
Accepted
May 9, 7:35 PM ET
Size
15.4 KB
Accession
0001225208-25-004947
Insider Transaction Report
Form 4
Lippis Daniel J.
CVP, TAVR
Transactions
- Award
Common Stock
2025-05-08+4,225→ 26,616.107 total - Sale
Common Stock
2025-05-09$74.42/sh−330$24,560→ 26,616.107 total - Award
Employee Stock Option (Right to Acquire)
2025-05-08+21,500→ 21,500 totalExercise: $74.63From: 2026-05-08Exp: 2032-05-07→ Common Stock (21,500 underlying) - Award
Performance Rights
2025-05-08+4,225→ 4,225 totalFrom: 2028-05-08→ Common Stock (4,225 underlying) - Exercise/Conversion
Common Stock
2025-05-09$45.28/sh+330$14,941→ 26,946.107 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2025-05-09−330→ 0 totalExercise: $45.28From: 2019-05-17Exp: 2025-05-16→ Common Stock (330 underlying)
Footnotes (5)
- [F1]These restricted stock units were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F2]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.
- [F3]This transaction was executed in multiple trades at prices ranging from $74.135 to $74.735. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F4]These options were granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F5]Reflects the target number of shares (the Target Award) covered by restricted stock unites granted on May 8, 2025 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 8, 2028. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.
Documents
Issuer
Edwards Lifesciences Corp
CIK 0001099800
Entity typeother
Related Parties
1- filerCIK 0002004380
Filing Metadata
- Form type
- 4
- Filed
- May 8, 8:00 PM ET
- Accepted
- May 9, 7:35 PM ET
- Size
- 15.4 KB